Unknown

Dataset Information

0

Serum TARC dynamics during anti‐PD1‐based first‐line Hodgkin lymphoma treatment: An analysis from the GHSG NIVAHL trial

ABSTRACT:

SUBMITTER: Plattel W 

PROVIDER: S-EPMC12371470 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature

Json Xml

Similar Datasets

Unknown Reverted exhaustion phenotype of circulating lymphocytes as immune correlate of anti-PD1 first-line treatment in Hodgkin lymphoma.
| S-EPMC8885413 | biostudies-literature
Unknown Elevated serum TARC levels precede classic Hodgkin lymphoma diagnosis by several years.
| S-EPMC10733822 | biostudies-literature
Unknown Blood-circulating EV-miRNAs, serum TARC, and quantitative FDG-PET features in classical Hodgkin lymphoma.
| S-EPMC9422001 | biostudies-literature
Unknown Serum TARC: a biomarker for early detection or exclusion of relapse in classic Hodgkin lymphoma.
| S-EPMC12455077 | biostudies-literature
Unknown Serum levels of TARC, MDC, IL-10, and soluble CD163 in Hodgkin lymphoma: a SWOG S0816 correlative study.
| S-EPMC6473498 | biostudies-literature
Unknown Plasma thymus and activation‐regulated chemokine (TARC) as diagnostic marker in pediatric Hodgkin lymphoma
| S-EPMC9176129 | biostudies-literature
Unknown Follow-up of the GHSG HD16 trial of PET-guided treatment in early-stage favorable Hodgkin lymphoma.
| S-EPMC10776396 | biostudies-literature
Unknown Programmed cell death protein1 (PD1)-expression in the microenvironment of classical Hodgkin lymphoma at relapse after conventional chemotherapy and at relapse on anti-PD1 treatment.
| S-EPMC6312031 | biostudies-literature
Unknown Clinical outcomes of relapsed and refractory Hodgkin lymphoma patients after contemporary first-line treatment: a German Hodgkin Study Group analysis.
| S-EPMC8885415 | biostudies-literature
Unknown Cure at what (systemic) financial cost? Integrating novel therapies into first-line Hodgkin lymphoma treatment.
| S-EPMC6913455 | biostudies-literature